These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29218254)

  • 1. Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling.
    Crenn V; Biteau K; Amiaud J; Dumars C; Guiho R; Vidal L; Nail LL; Heymann D; Moreau A; Gouin F; Redini F
    Am J Cancer Res; 2017; 7(11):2333-2349. PubMed ID: 29218254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
    Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
    Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
    Kim SH; Shin KH; Moon SH; Kong Y; Suh JS; Yang WI
    J Surg Oncol; 2017 May; 115(6):752-759. PubMed ID: 28403564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness and safety of polyethylene glycol liposome doxorubicin in the treatment of osteosarcoma].
    Yang YK; Xu HR; Huang Z; Li Y; Niu XH
    Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):692-696. PubMed ID: 32867464
    [No Abstract]   [Full Text] [Related]  

  • 5. Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
    Fan Z; Patel S; Lewis VO; Guadagnolo BA; Lin PP
    Clin Orthop Relat Res; 2015 Nov; 473(11):3604-11. PubMed ID: 26197952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
    Rha SY; Chung HC; Gong SJ; Shim KY; Ahn JB; Yang WI; Shin KH; Yoo NC; Kim JH; Roh JK; Lee CI; Kim BS
    Oncol Rep; 1999; 6(3):631-7. PubMed ID: 10203605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between apparent diffusion coefficient and histopathology subtypes of osteosarcoma after neoadjuvant chemotherapy.
    Wang J; Sun M; Liu D; Hu X; Pui MH; Meng Q; Gao Z
    Acta Radiol; 2017 Aug; 58(8):971-976. PubMed ID: 27852643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
    Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
    Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.
    Hauben EI; Weeden S; Pringle J; Van Marck EA; Hogendoorn PC
    Eur J Cancer; 2002 Jun; 38(9):1218-25. PubMed ID: 12044509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
    Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
    Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
    Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
    J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
    Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
    Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma.
    Tsuchiya H; Tomita K; Mori Y; Asada N; Morinaga T; Kitano S; Yamamoto N
    Anticancer Res; 1998; 18(1B):657-66. PubMed ID: 9584049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.
    Schwartz CL; Wexler LH; Krailo MD; Teot LA; Devidas M; Steinherz LJ; Goorin AM; Gebhardt MC; Healey JH; Sato JK; Meyers PA; Grier HE; Bernstein ML; Lipshultz SE
    Pediatr Blood Cancer; 2016 Jan; 63(1):54-61. PubMed ID: 26398490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.
    Matsuda K; Miyoshi H; Hiraoka K; Hamada T; Nakashima K; Shiba N; Ohshima K
    Clin Orthop Relat Res; 2018 Sep; 476(9):1848-1855. PubMed ID: 30024460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IS THERE ANY DIFFERENCE IN THE PROGNOSIS FOR PATIENTS WITH PRIMARY OSTEOSARCOMA WITH A POOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY BETWEEN HUVOS GRADES I AND II?
    Bispo Júnior RZ; Camargo OP
    Rev Bras Ortop; 2011; 46(4):420-3. PubMed ID: 27027032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
    Piperno-Neumann S; Ray-Coquard I; Occean BV; Laurence V; Cupissol D; Perrin C; Penel N; Bompas E; Rios M; Le Cesne A; Italiano A; Anract P; de Pinieux G; Collard O; Bertucci F; Duffaud F; Le Deley MC; Delaye J; Brugieres L; Blay JY
    Int J Cancer; 2020 Jan; 146(2):413-423. PubMed ID: 31246277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of intra-arterial chemotherapy and embolization before limb salvage surgery for osteosarcoma of the lower extremity.
    Zhang HJ; Yang JJ; Lu JP; Lai CJ; Sheng J; Li YX; Hao Q; Zhang SM; Gupta S
    Cardiovasc Intervent Radiol; 2009 Jul; 32(4):672-8. PubMed ID: 19296158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute.
    Bacci G; Ferrari S; Forni C; Mercuri M; Picci P; Bertoni F; Capanna R; Manfrini M; Donati D; Brach Del Prever A; Baldini N
    Chir Organi Mov; 1996; 81(4):369-82. PubMed ID: 9147928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.